Sugen Kinase 269 polyclonal antibody

PEAK1 (Pseudopodium-enriched atypical kinase 1 or sgk269) is a member of nonreceptor atypical tyrosine kinase family identified by MS analysis of purified psedopodium. PEAK1 is a multi-domain protein with a N-terminal Erk binding site, followed by actin-targeting/Src substrate/Erk substrate region, Crk binding site, Shc binding site, and a C-terminal kinase domain. By interacting with different adaptors like Shc, Grb2, Src, and others, PEAK1 functions as an important regulator in different signaling pathways, namely the Src/PEAK1/ErbB2, EGFR Shc1/PEAK1/Grb2, TGFβ/PEAK1/Src/MAPK, and fibronectin/PEAK1/Src pathways. PEAK1 plays an instrumental role in a wide variety of biological processes including epithelial-mesenchymal transition (EMT), dynamics of focal adhesion, cancer metastatic growth and invasion as well as cancer drug resistance. Phosphorylation of PEAK1 at Tyr665 or Tyr635 by SFK (Src family Kinases) has been shown to be essential for cancer cell migration and invasion as well as the turnover of focal adhesions.

The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen and the purity is > 95% (by SDS-PAGE) .